Atlas FDA

LIAISON XL MUREX Anti-HBe and LIAISON XL MUREX Control Anti-HBe

FDA premarket approval P180049/S017 · decided 2025-01-06

Approval details

PMA number
P180049
Supplement
S017
Supplement type
30-Day Notice
Supplement reason
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Trade name
LIAISON XL MUREX Anti-HBe and LIAISON XL MUREX Control Anti-HBe
Generic name
Test, Hepatitis B (B Antigen, B Surface Antigen, Be Antigen)
Applicant
DiaSorin, Inc.
Date received
2024-12-10
Decision date
2025-01-06
Days to decision
27 days
Decision code
OK30
Product code
LOM
Advisory committee
Microbiology
Expedited review
No
Location
Stillwater, MN
Statement
a new piece of equipment required for manufacturing

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
LIAISON Murex HBsAg Qual; LIAISON XL; LIAISON diluteX (K260770)DiaSorin, Inc.2026-06-04
LIAISON® XL MUREX Anti-HDV (318260); LIAISON® XL MUREX Control Anti-HDV (318261) (DEN250032)DiaSorin, Inc.2025-12-23
LIAISON VZV IgG HT, LIAISON Control VZV IgG HT (K231214)DiaSorin, Inc.2023-10-27
LIAISON Anti-HAV; LIAISON XS (K223403)DiaSorin, Inc.2022-12-09
LIAISON Calprotectin, LIAISON Q.S.E.T. Device Plus (K213858)DiaSorin, Inc.2022-07-26
LIAISON MeMed BV, LIAISON MeMed BV Control Set (K213936)DiaSorin, Inc.2022-07-14
LIAISON Ferritin (K193650)DiaSorin, Inc.2021-09-14
LIAISON Lyme IgM, LIAISON Lyme IgM Control Set, LIAISON Lyme Total Antibody Plus (K202573)DiaSorin, Inc.2021-02-18